Loading…
← CockpitCompetitor Analysis › 185750.KS ChongkundangOpen in the cockpit ↗

Chongkundang185750.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum strong 63
Mkt cap
$609M
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$796,760
20-day average traded
Fwd P/E
11.4×
forward earnings
ROIC−WACC
+0.1 pp
WACC 5.2%
Hurdle
-12 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · KRW₩60,800
1D-1.1%
1W-2.2%
1M-9.1%
3M-11.0%
6M-26.6%
YTD-26.7%
1Y-27.4%
ATR %3.5%
52w lowhigh38.0% off high

What Chongkundang does

Employees: 2,304

Chongkundang at a glance

Size Chongkundang (185750.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $609M, the 315th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩60,800 on 18 Nov 2026.

Performance Over six months the shares fell 26.6%, against -25.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 6.3% over the last twelve months (peer median +2.6%); the operating margin is 4.4% (peer median 4.1%).

Valuation It trades at 11.4× forward earnings against a peer median of 18.5× (4th cheapest of 7).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points above its cost of capital (5.2% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 76185750.KS 75
Six months, rebased to 100: Chongkundang against the median of its 20 peers (local-currency closes).

Chongkundang financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.79T₩1.69T₩1.59T₩1.67T₩1.49T
Revenue growth—+7%-5%+12%—
Gross profit₩524B₩517B₩524B₩655B₩537B
EBITDA₩125B₩125B₩139B₩284B₩144B
Net income₩78.2B₩77.5B₩109B₩213B₩81.0B
Free cash flow₩122B-₩73.5B₩25.8B₩277B₩23.2B
Capital expenditure₩144B₩179B₩66.1B₩68.8B₩52.7B
Total debt₩426B₩368B₩188B₩220B₩236B

Quarterly statements and history in the cockpit →

Chongkundang competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%002793603567002940300194ORCHPHARMADBV3002334105OLMA301211600976IMMXBCAX300147300878CGEM603439185750.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Chongkundang is the large dot.

Fundamentals: revenue growth against valuation

-75%-50%-25%0%0×25×50×75×603567ORCHPHARMA4105301096600976603439185750.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongkundang is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%0027936035670029403001943002334105600976300147603439185750.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chongkundang is the large dot.

Chongkundang competitors and peer comparison

How Chongkundang compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongkundang against its 20 peers (data as of 18 Nov 2026)
Measure185750.KSPeer medianRank in peer set
1-month return-9.1%-11.8%9th highest of 20
6-month return-26.6%-25.9%10th lowest of 20
Distance from 52-week high-38.0%-43.9%8th highest of 20
Revenue growth (TTM)+6.3%+2.6%5th highest of 15
Operating margin4.4%4.1%7th highest of 14
Forward P/E11.4×18.5×4th cheapest of 7
Growth the price implies (Req g, 7 yrs)-6.6%9.1%2nd least demanding of 10
Growth delivered (Del g)+5.4%-1.6%4th highest of 10
Hurdle (Req g minus delivered)-11.9 pp+8.1 pp3rd least demanding of 10
ROIC minus cost of capital+0.1 pp-4.7 pp5th highest of 13
EV / EBITDA7.0×n/a—
Net debt / EBITDA0.5×-0.4×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%

Questions

Which companies are Chongkundang's closest peers?
The cockpit's peer set: Luoxin Pharmaceuticals Group Stock (002793.SZ), Achieve Life Sciences (QUIT), HeiLongJiang ZBD Pharmaceutical (603567.SS), Zhejiang Anglikang Pharmaceutical (002940.SZ), Fuan Pharmaceutical (Group) (300194.SZ), Orchid Pharma (ORCHPHARMA.NS), DBV Technologies (DBV.PA), Shandong Jincheng Pharmaceutical (300233.SZ).
Is Chongkundang expensive compared with its peers?
On forward p/e it trades at 11.4× against a peer median of 18.5×, 4th cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Chongkundang stock performed?
Over six months to 18 Nov 2026 the shares returned -26.6% against -25.9% for the median peer; over one year -27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.